DC-HIL/Gpnmb is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
Immune checkpoint inhibitors (ICI) benefit only a minority of treated cancer patients. Identification of biomarkers distinguishing responders and non-responders will improve management of cancer patients. Since the DC-HIL checkpoint differs from the PD1 pathway in expression and inhibitory mechanisms, we examined whether DC-HIL expression regulates ICI responsiveness. Plasma samples were collected from advanced non-small cell lung carcinoma (NSCLC) patients (n=76) at baseline and/or follow-up after ICI monotherapy. Blood soluble DC-HIL (sDC-HIL) was determined and analyzed for correlation with the early tumor response. To study the mechanisms, we measured effect of anti-DC-HIL vs. anti-PDL1 mAb on growth of mouse tumor cells in experimentally metastatic lung. Influence of DC-HIL to anti-PDL1 treatment was assessed by changes in tumor response after deletion of host-DC-HIL gene, injection of DC-HIL-expressing myeloid-derived suppressor cells (MDSC) or induction of sDC-HIL expression. Non-responders expressed significantly higher levels of baseline sDC-HIL levels compared to responders. Among patients (n=28) for fluctuation with time, non-responders (14/15 cases) showed increasing or persistently elevated levels. Responders (12/13) had decreasing or persistently low levels. Among various tumors, B16 melanoma exhibited resistance to anti-PDL1, but responded to anti-DC-HIL mAb. Using B16 melanoma and LL2 lung cancer, we showed deletion of host-derived DC-HIL expression converted the resistant tumor to one responsive to anti-PDL1 mAb. The responsive state was revered by infusion of DC-HIL+MDSC or induction of sDC-HIL expression. sDC-HIL in the blood and probably DC-HIL receptor expressed by MDSC plays an important role in regulating response to ICI in advanced NSCLC.